

2026 KNOWLEDGE-BASED HOME-STUDY CE FOR PHARMACISTS AND PHARMACY TECHNICIANS FROM GUIDELINES TO BEDSIDE: EVOLVING HIV CARE IN HOSPITALIZED PATIENTS

Speaker: Shannon Balcombe, PharmD, BCPS, AAHIVP, Clinical Pharmacist - HIV, Transitions of Care, UC San Diego Health System, San Diego, CA

Pharmacist and Pharmacy Technician Objectives

- Review key considerations for starting, continuing, or adjusting antiretroviral therapy (ART) in hospitalized adults with HIV
- Summarize key steps for medication reconciliation and safe transitions of care to prevent ART errors during and after hospitalization
- Outline US Department of Health and Human Services (DHHS) guidance on management of HIV infection, including when to start ART during acute illness and opportunistic infections
- Discuss strategies for addressing social determinants of health and ensuring linkage to outpatient HIV care after discharge, as recommended by the US DHHS

Accreditation Information:

ACPE UAN: 0122-0000-26-046-H02-P/T (HIV/AIDS CE)

CE Credit Hours: 1.0 hour (0.1 CEU) of live CE credit

Release Date: May 25, 2026

Expiration Date: May 25, 2029

Disclosure: Dr. Balcombe, the moderators and planners for this activity have no relevant financial relationship(s) with ineligible companies to disclose.

Sponsorship: This program is conducted solely by Premier and has no commercial or non-commercial support or sponsorship.

System Requirements to Access the Webinar: Click [here](#) to view CE webinar system requirements for the learner to complete the online activity, including the internet browser(s) supported and minimum versions of each, and the minimum memory, storage, processor, and internet

How to obtain CE credit

1. Log on to <https://ce.pharmacy.premierinc.com>
2. Click on the icon that corresponds to this Home-Study CE activity
3. Register for that Home-Study CE activity
4. View and listen to the recorded activity in its entirety
5. Complete both the learning assessment questions and the activity evaluation.

Note: CPE participation will be provided to CPE Monitor if the participant attains a passing grade of 70% or better on the post-test learning assessment questions. NABP e-profile ID number and birthdate (MMDD) must be provided by participants to receive CE credit.



Premier, Inc. is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. This CE activity is provided as a free, value-added service to Premier pharmacy staff.

For any questions, please contact [Premier's Pharmacy Team](#).

**2026 KNOWLEDGE-BASED HOME-STUDY CE
FOR PHARMACISTS AND PHARMACY TECHNICIANS
FROM GUIDELINES TO BEDSIDE:
EVOLVING HIV CARE IN HOSPITALIZED PATIENTS**

Speaker:

Shannon Balcombe, PharmD, BCPS, AAHIVP

Clinical Pharmacist – HIV, Transitions of Care

UC San Diego Health System

San Diego, CA

Speaker Bio:

Shannon Balcombe, PharmD, BCPS, AAHIVP is an inpatient HIV and transitions of care specialist pharmacist at UC San Diego Health, where she has provided direct clinical care to hospitalized people with HIV for over a decade. She earned her Doctor of Pharmacy degree magna cum laude from Northeastern University, completed her PGY1 Pharmacy Practice Residency at UC San Diego Health, and her PGY2 Critical Care Residency at the University of Washington Medical Center. Board Certified in Pharmacotherapy and credentialed as an HIV Pharmacist by the American Academy of HIV Medicine, Dr. Balcombe's work centers on optimizing antiretroviral management and ensuring continuity of care for complex patients during and after hospitalization.

At UC San Diego, she is an active preceptor and lecturer in UC San Diego's residency and infectious diseases training programs. She is an active member of the Pharmacy Research Council, with publications examining antiretroviral pharmacology, medication-related outcomes, and drug-drug interactions in people with HIV. In her spare time, she enjoys trying to perfect plant-based cooking and reading fiction.

Disclosure: Dr. Balcombe, the moderators and planners for this activity have no relevant financial relationship(s) with ineligible companies to disclose.